Medlive Technology Co., Ltd. 2025 Annual Report — In-Depth Analysis for Investors

Key Financial and Operational Highlights

• Adjusted Net Profit Margin: The Group’s adjusted net profit margin for the year ended 31 December 2025 stood at 53.3%, down from 57.9% in 2024. This 4.6 percentage point decline was mainly due to the US Federal Reserve’s interest rate cuts from March 2025, which impacted the Group’s interest income as a proportion of revenue, resulting in a decrease of 9.0 percentage points compared to 2024.
• Interest Income & Wealth Management: The Group generated RMB61.9 million in interest income from wealth management products, such as certificates of deposits, notes, and bonds, with returns ranging between 3.20% and 5.50%. As of 31 December 2025, RMB1,807.0 million was invested in such products, reflecting the Group’s prudent treasury management approach aimed at maximizing unused capital returns.
• Liquidity & Working Capital: The Board asserts that the Group has sufficient working capital to meet operational needs for at least the coming 12 months. The Group’s liquidity is supported by cash generated from operations and proceeds from the 2021 Global Offering, part of which is invested in short to medium-term wealth products issued by reputable banks.
• Dividend Policy & Distribution: The Board has recommended a final dividend of RMB0.1435 (equivalent to HK\$0.1629) per share, subject to approval at the annual general meeting. The payout reflects the company’s policy to balance returns to shareholders with business development needs and financial health.
• IPO Proceeds Utilization: The Group raised HK\$4,677 million in its IPO (including the over-allotment option). As of 31 December 2025, HK\$3,039.3 million remains unutilized, with HK\$903.2 million parked in wealth management products and the rest in deposits with licensed financial institutions. Remaining funds are slated for business expansion, R&D, strategic investments, and working capital replenishment, with completion targeted by December 2027.

Strategic and Operational Developments

• Business Segments: The Group primarily serves pharmaceutical and medical device companies, hospitals, research institutes, contract research organizations, physicians, healthcare professionals, and patients through its precision marketing, knowledge solutions, and patient management platforms.
• Customer Concentration Risk: The Group’s revenues are exposed to a limited number of major customers, with the top five customers contributing less than 30% of total revenue in 2025. All major customers are independent third parties, and there were no disputes with any key customers or suppliers.
• Technology and Data Security Risks: The Group’s operations depend heavily on IT systems and data analytics, exposing it to cybersecurity and data protection risks. Any breach could result in significant reputational, regulatory, and financial consequences.
• Regulatory Structure: The Group uses contractual arrangements (VIE structure) to control certain subsidiaries in the PRC. Risks remain if PRC authorities challenge this structure, which could severely impact operations and financial results. The Company has received waivers from the Hong Kong Stock Exchange for certain connected transaction requirements related to these arrangements.

Share Incentive Schemes and Share Capital Movements

• Share Option & Award Plans: The Group operates pre-IPO and post-IPO share option schemes as well as a share award scheme. As of 31 December 2025, 69,017,600 shares (9.34% of issued share capital) remain available for grant under these schemes. During 2025, 4,154,875 share options were exercised, resulting in the issuance of an equivalent number of shares.
• Share-based Payment Expense: In 2025, the Group recognized RMB1.22 million as share option expense and RMB1.11 million as share award expense. A total of 500,000 share awards were granted in 2022, vesting over eight years, with strict performance conditions attached to each tranche.
• Share Capital: The Company’s issued share capital increased to 737,030,875 shares after new share issues for share award exercises. The share premium and retained profits together amount to approximately RMB3,974.1 million as distributable reserves as at 31 December 2025.

Corporate Governance and Board Structure

• Board Diversity & Skills: The Board consists of four executive Directors (founders with at least 20 years’ experience), two non-executive Directors (from M3, Inc., an industry peer), and three independent non-executive Directors (with medical, financial, and accounting backgrounds). One-third of the Board are female, reflecting a commitment to diversity and governance.
• Risk Management & Internal Controls: The Board and Audit Committee confirm that Group’s internal controls and risk management systems were adequate and effective in 2025. From 2026, the Company will use a risk heat map for risk assessment and ongoing monitoring.
• Public Float: The Company maintains sufficient public float (>24.98%) as required by the Hong Kong Stock Exchange under an approved waiver.

Other Notable Items

• Charitable Donations: The Group made RMB100,000 in charitable donations in 2025, down from RMB169,992 in 2024.
• No Significant Events Post Year-End: There were no significant events after 31 December 2025 requiring additional disclosure or adjustment.
• Gearing Ratio: The Group had zero gearing as of year-end, with no outstanding borrowings.
• External Auditor: Ernst & Young was paid RMB2.0 million for audit services in 2025, with no non-audit fees incurred.

Shareholder and Price-Sensitive Information

• Dividend Recommendation: The recommended final dividend, if approved, provides a direct return to shareholders and may influence share price upon announcement and payment.
• Utilization of IPO Proceeds: The large unutilized balance of IPO proceeds, mainly invested in wealth management products, means the Company retains significant financial flexibility for future investments and operations. However, this also means that future large-scale investments, M&A, or expansion plans could impact the Company’s risk profile and earnings trajectory.
• Regulatory Risks Related to VIE Structure: Any adverse regulatory action or change in the PRC’s stance on VIE structures could have a material and immediate impact on the Group’s operations and valuation.
• Customer Concentration: While current major customers are independent and no director/shareholder holds an interest, the risk remains that the loss of a major customer could significantly affect future revenue and profitability.
• Share-Based Compensation Dilution: Ongoing share grants and option exercises could lead to dilution of existing shareholders’ interests, especially if large tranches are vested or exercised in future years.

Conclusion

Medlive Technology remains financially robust, with strong liquidity and no debt. Its prudent treasury management, ongoing investments in R&D and technology, and commitment to returning value to shareholders via dividends are notable positives. However, investors should monitor regulatory developments on VIE structures in China, the deployment of IPO proceeds, and the Group’s ability to diversify its customer base and sustain profit margins in a changing macroeconomic environment.

Potential Share Price Drivers: Dividend declarations, large deployments of IPO proceeds, regulatory actions on VIEs, major contract wins or losses, and significant share-based compensation events could meaningfully impact the Company’s share price.

Disclaimer: This article is based on the 2025 Annual Report of Medlive Technology Co., Ltd. and is provided for informational purposes only. It does not constitute investment advice. Investors should conduct their own due diligence and consult their financial advisor before making investment decisions. The author and publisher accept no liability for any loss arising from reliance on this report.